Biotech Values

[DewDiligence]

Quiz (medium-high difficulty): IDIX recently reported positive data for IDX899 in treatment-naive HIV at a dose 800mg qD (#msg-26606685). There were no safety or tolerability issues, but IDIX intends to conduct additional cohorts in the trial at 400, 200, and 100mg qD.

IDIX cited a rationale for testing lower doses other than the obvious desire to avert cumulative toxicity when IDX899 is combined with such standard HIV drugs as Truvada. What is the other rationale for going lower?

Note: dose escalation up to 800mg has already been conducted in a separate phase-1 trial.